Altos Labs Cellular Rejuvenation — Gene Therapy & Genetic Interventions
Industry-leading cellular reprogramming program backed by $3B in funding, developing epigenetic rejuvenation therapies.
Overview
Altos Labs is a biotechnology company founded in 2022 with $3 billion in initial funding, focused on cellular rejuvenation through epigenetic reprogramming. Led by scientists including Juan Carlos Izpisua Belmonte, Shinya Yamanaka (advisory), and Steve Horvath, Altos is developing next-generation reprogramming approaches that go beyond OSKM factors. Their research includes identifying optimal factor combinations, delivery systems, and tissue-specific protocols. While specific pipeline details remain largely confidential, published research from Altos scientists has demonstrated age reversal in multiple tissue types and whole organisms.
Indications
- Age-related disease (broad indication)
- Tissue regeneration and repair
- Neurodegenerative disease
- Epigenetic age reversal
- Organ rejuvenation
Mechanism of Action
Proprietary combinations of transcription factors and/or small molecules delivered to target tissues
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Altos Rejuvenation Therapy | Not disclosed | Not disclosed | Proprietary program; details confidential |
Safety & Contraindications
- Specific safety data not publicly available for proprietary programs
- General reprogramming risks apply: oncogenesis, dedifferentiation, immune activation
- Company pursuing safety-first approach with extensive preclinical characterization
- No clinical trials initiated as of current date
- Regulatory pathway for aging indications remains undefined